Synthobolic Extreme Synthol – Guaranteed Size and Muscle Definition

Gone are the days when a great physique was a characteristic feature of people serving in the armed forces or sports persons or athletes. The modern world in a health conscious world where a physically fit body is considered to be one of the most valuable assets that a human being can possess or is Read more about Synthobolic Extreme Synthol – Guaranteed Size and Muscle Definition[…]

Genzyme, AGTC Announce Gene Therapy Collaboration

Genzyme Corporation and Applied Genetic Technologies (AGTC), a private development-stage biotechnology company, announced today that they have entered into a research collaboration to jointly develop novel therapeutics involving gene therapy.Through the collaboration, Genzyme gains access to AGTC’s extensive expertise using Adeno-Associated Virus (AAV) vectors to deliver genes to patients, including access to AGTC’s novel high-yield Read more about Genzyme, AGTC Announce Gene Therapy Collaboration[…]

Combimatrix Achieves Milestone In Strategic Alliance With Toppan

Acacia Research Corporation announced its CombiMatrix Group has achieved a milestone in its multi-year strategic alliance with Toppan, resulting in a $1,250,000 payment. CombiMatrix received an initial $1 million upfront payment in May of this year from Toppan when the alliance was formed. Amit Kumar, Ph.D., President and Chief Executive Officer of CombiMatrix, commented, “We Read more about Combimatrix Achieves Milestone In Strategic Alliance With Toppan[…]

Discovery Services Agreement For Novartis And Transgenomic

Transgenomic Inc. has entered into several specific agreements with Novartis Pharmaceuticals Corp. to provide mutation discovery services in the context of translational research programs in oncology. The goal is to support biomarker discovery efforts in the context of clinical trials by identifying genetic mutations that correlate with patients’ response(s) to cancer therapeutics. Transgenomic has performed Read more about Discovery Services Agreement For Novartis And Transgenomic[…]

Xenerex And Peregrine Announce Research Collaboration

Xenerex Biosciences, a subsidiary of AVANIR Pharmaceuticals, and Peregrine Pharmaceuticals, Inc. have announced that they have entered into an antibody research collaboration agreement, designed to discover, develop and potentially commercialise fully human monoclonal antibody therapies for the treatment of solid tumour cancers. “Our opportunity to work with Peregrine is yet another step forward in validating Read more about Xenerex And Peregrine Announce Research Collaboration[…]

Buying Dragon Pharma Safely